U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
Western biotechs get new playbook with tighter controls to stay ahead of ultraefficient pharmaceutical pipeline overseas
July 9, 2026 The Wall Street Journal
Steve Potts is developing medicines for hard-to-treat cancers. Just don’t ask what, exactly, he is working on. If word gets out, he fears a Chinese company could beat him to market.
Potts’s company, whose team has shepherded a combined 13 drugs through Food and Drug Administration approval, is one of a growing number of biotechs going to extreme lengths to stay secret. He won’t pitch venture-capital firms. He hasn’t presented at academic conferences. The company, Breakthru Medicine, is taking money only from a handful of trusted, high-net-worth individuals and universities.
For decades, young biotechs broadcast their science publicly to attract investment. Today, more are going dark to keep rivals, many of which are based in China, from replicating their research and doing studies in humans even faster than they can.
“You have to be much more thoughtful with how much you’re talking about what you’re working on,” Potts said.
Today, when a drug company publishes a successful clinical trial at a major medical conference, it runs the risk that a firm in China will replicate their work, launching competing clinical trials using the same science. Research in China can in some cases move twice as fast and cost half as much as within the U.S. That has allowed Chinese biotechs to become a bigger threat to the U.S. industry and has caused drugmakers big and small to rethink how much information they share about promising new science.
Even larger companies have tight controls when doing clinical trials with partners in China. Biogen doesn’t share any proprietary information beyond what is required by Chinese regulators.
“Fast followership is a real concern,” said Priya Singhal, Biogen’s head of development. She said Chinese biotechs have “gotten very good with pretty-well-known targets—in bettering them, in really getting more precise.”
For smaller biotechs, this dynamic creates a paradox. Pitching dozens of investors—the traditional path to funding—spreads proprietary science to exactly the audience that can leak it. Staying secret limits companies to small, private capital pools that are hard to access without connections.
“We used to get by in an imperfect system because the venture world would capitalize a good idea,” said Karen Knudsen, chief executive of the Parker Institute for Cancer Immunotherapy. But now, instead of wanting to see a promising idea before studies begin, she said, investors want to see proof that a drug might work in patients, which is easier to get from China, where trials move faster.
The number of early-stage trials run in China in 2025 was about five times as high as a decade prior, while the number of similar trials run in the U.S. has stagnated, according to Norstella, a life-sciences company.
That has led bigger companies to buy some of that science from China. Executives at big drug companies said they are considering doing deals for early-stage drugs from China more than ever before.
Congress is trying to choke off some of the investment U.S. companies are making in Chinese firms. Lawmakers introduced a bill last month to require investments in Chinese drugmakers to be screened by the Treasury Department, which has the potential to stop certain deals from getting done. Some lawmakers are also trying to change regulations so the FDA can’t accept clinical-trial data from China altogether.
Meanwhile, the growth in the number of so-called fast-follower drugs from China shows no sign of slowing. The number of drugs from China that fit into that category increased by a factor of 15 from 2015 to 2025, according to Norstella.
ELI LILLY
NOVO NORDISK
Conference presentation
Academic article
Catalyst event
GLP-1
2019
’26
Lung cancer target
AMGEN
Conference presentation
Licensed to Western partner
After Novo Nordisk published landmark results in February 2021 showing strong results for its weight-loss drug semaglutide, at least 16 Chinese programs targeting the same mechanism filed for clinical-trial approval or dosed patients in China within 18 months, according to the biopharma market-intelligence firm Sleuth, and at least 62 such Chinese programs have launched through June 2026.
Many ended up back in Western companies’ hands. Thirteen programs were licensed back to U.S. and European pharma giants—including to Novo Nordisk, which bought a Chinese version of a drug program built on its own discovery.
A similar cascade hit oncology in late 2023, when Amgen presented data showing it could target a hard-to-treat protein on small-cell lung cancer cells. A Chinese company started laying the groundwork for a competing trial within six weeks. At least 10 separate programs entered clinical development in China targeting the same protein within 18 months.
The race has reached genetic medicine, some of the most advanced science being used in labs today. Cambridge, Mass.-based Beam Therapeutics developed an experimental treatment for a rare inherited disease that damages the lungs and liver, dosing its first patient in 2024. A former Beam employee had already joined Shanghai-based YolTech Therapeutics in 2022, building a rival drug with the exact same target using the same technology. The former employee said she didn’t work on Beam’s competing drug while at the company.
YolTech’s treatment won U.S. regulatory clearance for a late-stage trial in March—two months after Beam struck its own deal with the FDA to speed its rival drug toward approval. Last month, a San Diego-based biotech company licensed YolTech’s drug.